Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen Propulsid concomitant use with Nizoral contraindicated due to association with arrhythmias.

Executive Summary

JANSSEN PROPULSID CONCOMITANT USE WITH NIZORAL CONTRAINDICATED because of the potential for prolonged QT interval and rare association with ventricular arrhythmia and torsades de pointes, new warnings in Propulsid's labeling state. Janssen Pharmaceutica informed pharmacists and physicians of the new safety information about the nocturnal heartburn treatment in letters sent out in early February.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS025888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel